Literature DB >> 17571910

New dosage formulations for targeted delivery of cyclo-oxygenase-2 inhibitors: focus on use in the elderly.

Shyam S Bansal1, Abhijeet Joshi, Arvind K Bansal.   

Abstract

NSAIDs are a widely used class of analgesic and anti-inflammatory drugs that act by inhibiting the cyclo-oxygenase (COX) enzyme. However, because of their nonspecificity of action, use of these agents as long-term therapy for chronic pain in diseases such as rheumatoid arthritis (RA) and osteoarthritis (OA) is often discouraged. Among NSAIDs, COX-2 inhibitors are promising candidates for long-term therapy of chronic diseases, particularly in the elderly, because of their reduced incidence of gastrointestinal adverse effects. However, in recent times these agents have also been shown to cause adverse effects such as cardiovascular effects (myocardial infarction, stroke and hypertension) and renal effects (decreased renal blood flow/glomerular filtration rate), which in 2004 led to the withdrawal of rofecoxib and in 2005 the withdrawal of valdecoxib from the US market. Importantly, these adverse effects can be effectively reduced by achieving site specific/targeted delivery through new formulation approaches. These formulations not only restrict the drug supply to specific organs but also reduce the dose required. As a result, use of new delivery systems such as nanoparticles, microparticles, microemulsions and nanogels has gained widespread applicability in the management of chronic disease, especially in the elderly, and particularly when there is a need to decrease dose-dependent adverse effects (as is the case with COX-2 inhibitors). This article reviews various new approaches to the delivery of COX-2 inhibitors and highlights issues related to the development of delivery systems for these agents for RA, OA, cancer (familial adenomatous polyposis, prostate, breast and non-small cell lung cancer), ocular diseases (such as diabetic retinopathy) and inflammatory diseases of the skin, with emphasis on their potential for use in the elderly. Emphasis is also placed on the preparation of these particulate systems, their release profile and behaviour in biological systems.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17571910     DOI: 10.2165/00002512-200724060-00001

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  71 in total

Review 1.  Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease.

Authors:  P L McGeer
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

Review 2.  Pharmacokinetics in older persons.

Authors:  Barry J Cusack
Journal:  Am J Geriatr Pharmacother       Date:  2004-12

3.  Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration.

Authors:  Aniruddha C Amrite; Uday B Kompella
Journal:  J Pharm Pharmacol       Date:  2005-12       Impact factor: 3.765

Review 4.  NSAIDs and blood pressure. Clinical importance for older patients.

Authors:  A G Johnson
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

5.  Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.

Authors:  Stephen P Motsko; Karen L Rascati; Anthony J Busti; James P Wilson; Jamie C Barner; Kenneth A Lawson; Jason Worchel
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

6.  Formulation and evaluation of aerosolized celecoxib for the treatment of lung cancer.

Authors:  Alfred Haynes; Madhu Sudhan Shaik; Abhijit Chatterjee; M Singh
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

Review 7.  Cyclooxygenase inhibitors--current status and future prospects.

Authors:  G Dannhardt; W Kiefer
Journal:  Eur J Med Chem       Date:  2001-02       Impact factor: 6.514

8.  Novel treatment for joint inflammation.

Authors:  J T Dingle; J L Gordon; B L Hazleman; C G Knight; D P Page Thomas; N C Phillips; I H Shaw; F J Fildes; J E Oliver; G Jones; E H Turner; J S Lowe
Journal:  Nature       Date:  1978-01-26       Impact factor: 49.962

9.  Nimesulide PLA microspheres as a potential sustained release system for the treatment of inflammatory diseases.

Authors:  M N Freitas; J M Marchetti
Journal:  Int J Pharm       Date:  2005-05-13       Impact factor: 5.875

10.  The use of albumin microspheres in the treatment of carrageenan-induced inflammation in the rat.

Authors:  D A Lewis; W N Field; K Hayes; H O Alpar
Journal:  J Pharm Pharmacol       Date:  1992-03       Impact factor: 3.765

View more
  4 in total

1.  Semi-solid topical formulations containing nimesulide-loaded nanocapsules showed in-vivo anti-inflammatory activity in chronic arthritis and fibrovascular tissue models.

Authors:  Quéli Fernandes Lenz; Sílvia Schaffazick Guterres; Adriana Pohlmann; Marta Palma Alves
Journal:  Inflamm Res       Date:  2011-12-18       Impact factor: 4.575

2.  Effects of indomethacin-loaded nanocapsules in experimental models of inflammation in rats.

Authors:  A Bernardi; A C C V Zilberstein; E Jäger; M M Campos; F B Morrone; J B Calixto; A R Pohlmann; S S Guterres; A M O Battastini
Journal:  Br J Pharmacol       Date:  2009-05-06       Impact factor: 8.739

Review 3.  The use of lipid-based nanocarriers for targeted pain therapies.

Authors:  Susan Hua; Sherry Y Wu
Journal:  Front Pharmacol       Date:  2013-11-21       Impact factor: 5.810

Review 4.  Can active components of licorice, glycyrrhizin and glycyrrhetinic acid, lick rheumatoid arthritis?

Authors:  Qing-Chun Huang; Mao-Jie Wang; Xiu-Min Chen; Wan-Lin Yu; Yong-Liang Chu; Xiao-Hong He; Run-Yue Huang
Journal:  Oncotarget       Date:  2016-01-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.